Change in leadership at STADA
- Press Release
- Hartmut Retzlaff lays down office as Chief Executive Officer due to medical reasons.
- Executive Board members Helmut Kraft and Dr. Matthias Wiedenfels jointly take over areas of responsibility previously overseen by the CEO
- Dr. Matthias Wiedenfels initially appointed Chief Executive Officer
Bad Vilbel, June 5, 2016 – The Supervisory Board of STADA Arzneimittel AG has decided on a change at the company’s helm at an extraordinary meeting held today. Due to a serious, long-term illness, the previous Chief Executive Officer Hartmut Retzlaff has to lay down his office with immediate effect until further notice. His existing duties will be assumed by the Executive Board members Hartmut Kraft and Dr. Matthias Wiedenfels. Initially Dr. Matthias Wiedenfels has also been appointed as Chief Executive Officer.
“Hartmut Retzlaff has shaped STADA. In his 23 years as CEO to date, he has successfully built and internationalized the company and diversified it unswervingly. STADA is now in better shape than ever. The fact that Mr. Retzlaff has been forced to lay down his office temporarily due to medical reasons comes as a surprise to us and saddens us deeply. But health has top priority. Together with all employees of STADA, the Supervisory Board wishes him a good and speedy recovery,” said Dr. Martin Abend, Chairman of the Supervisory Board.
Helmut Kraft, who has been on the Executive Board since 2010 and is responsible for Finance, will also take charge of Marketing & Sales, Purchasing/Supply Chain Management as well as Research & Development. Dr. Matthias Wiedenfels, who has been the member of the Executive Board responsible for Corporate Development & Central Services since 2013, will also be in charge of Corporate Strategy, Corporate Communication as well as Production. Until further notice Dr. Matthias Wiedenfels will also take over as Chief Executive Officer.
Dr. Martin Abend stated about the appointment: “With Matthias Wiedenfels, an experienced, long-serving manager is initially taking over at the helm of the Executive Board. He has played an influential part in the group’s positive development in the past years and he will consequently drive forward the initiated change for the benefit of the company. With that he stands for continuity as well as the ability to give the company the continuously necessary new impulses. We are sure that STADA will continue to develop exceptionally successful, not only because of a growth strategy that is acknowledged in the market and with highly motivated employees.”
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com
Or visit us in the Internet at www.stada.com.